Kardi Ai launches long-term ECG monitoring in India

HYDERABAD: Czech healthtech company Kardi Ai on Saturday launched its AI-supported long-term ECG monitoring system in India, presenting the wearable chest-strap platform to cardiologists and hospital stakeholders at Daspalla Hotel in Jubilee Hills.

The product pairs a lightweight ECG strap with mobile connectivity and software that helps physicians review longer rhythm recordings while patients go about daily life. Co-founder and CEO Ing. Vlastimil Hrabal told the gathering the goal is to make extended monitoring simpler than relying only on a brief clinic ECG or a conventional 24-hour Holter study.

Arrhythmias can come and go. A short strip in an outpatient room, or even a one-day Holter, may miss episodes that appear days later. Kardi Ai positions longer outpatient recording as a way to raise the chance of catching those intermittent events, with AI tools assisting the clinician's review rather than replacing diagnosis.

How the system is meant to work

Patients wear the chest strap for an extended period set by the prescribing doctor. Recorded signals move through a mobile platform for analysis. Clinicians then examine flagged segments and full traces as part of their own judgment. The company describes the offering as prescription-grade medical technology, not a consumer fitness band.

Kardi Ai has cited detection rates of up to about 40 percent with its approach, against roughly 2 to 5 percent it attributes to conventional Holter monitoring in comparable settings. Those figures are company-reported. Outcomes can vary with protocol length, patient mix and how arrhythmia is defined in a given study. Indian hospitals will need local clinical experience before treating any percentage as a standard claim.

According to the company, the product holds an MD-15 licence from the Government of India for import and sale. It is also described as CE marked and classified as an EU MDR Class IIa medical device, with a quality system aligned to ISO 13485. Buyers and hospitals should verify the exact licence scope on official paperwork before procurement.

India partnership and next steps

Hyderabad-based Eurasia Medical Technologies LLP is acting as Kardi Ai's Indian representative. CzechTrade India officials attended the launch and framed the entry as part of wider Czech healthtech interest in the Indian market. Local clinicians present, including Dr Ramana Jagarlamudi and Dr Raghavendra Rao, pointed to rising interest in remote monitoring and AI-assisted review tools in cardiac practice.

Discussions about eventual manufacturing in India were mentioned as exploratory, not as a signed factory plan. Pricing for Indian patients, insurance pathways and hospital integration timelines were not announced at the event.

For Indian readers, the practical news is that another long-term ECG option is entering through a formal medical-device route, with a Hyderabad launch footprint. Adoption will still hinge on cardiologist comfort, hospital IT hooks and clear clinical protocols. Patients who think they need extended monitoring should speak to a doctor rather than treat any wearable ECG pitch as a self-test kit.

Reporting basis: Kardi Ai India launch programme on 27 September 2026 at Daspalla Hotel, Jubilee Hills, Hyderabad; statements by Co-founder and CEO Ing. Vlastimil Hrabal; company disclosures on MD-15 licensing, CE / EU MDR Class IIa status and ISO 13485 alignment; role of Eurasia Medical Technologies LLP as Indian representative.